Drug duo aims to supercharge weight loss in new trial
NCT ID NCT06965413
Summary
This study is testing whether adding a new investigational drug called RO7204239 to an existing weight-loss medication (tirzepatide) helps people lose more weight. It will involve about 285 adults who have obesity or are overweight with at least one related health issue, like high blood pressure, but do not have diabetes. Participants will receive the drug combination or a placebo for 48 weeks to see which leads to greater body weight reduction.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accellacare North London
Northwood, HA6 2RN, United Kingdom
-
Accellacare Research of Winston Salem
Winston-Salem, North Carolina, 27103, United States
-
Accellacare South London
Orpington, BR5 3QG, United Kingdom
-
Accellacare Warwickshire
Coventry, CV3 4FJ, United Kingdom
-
Accellacare Yorkshire
Shipley, Yorkshire, BD18 3SA, United Kingdom
-
Accellacare of Bristol/ Internal Medicine & Pediatrics
Bristol, Tennessee, 37620, United States
-
Accellacare of Duly Health and Care
Oak Lawn, Illinois, 60453, United States
-
Accellacare of Knoxville
Knoxville, Tennessee, 37912, United States
-
Accellacare of Piedmont Healthcare
Statesville, North Carolina, 28625, United States
-
Accellacare of Salisbury
Salisbury, North Carolina, 28144, United States
-
Accellacare of Wilmington, LLC
Wilmington, North Carolina, 28401, United States
-
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Pomeranian Voivodeship, 80-546, Poland
-
Centrum Medyczne ALL-MED
Krakow, 30-033, Poland
-
Clinical Research Associates
Nashville, Tennessee, 37203, United States
-
Consano Clinical Research
Shavano Park, Texas, 78231, United States
-
ETG Warszawa
Warsaw, 02-677, Poland
-
Ekamed sp. z o.o.
Lublin, 20-718, Poland
-
Encompass Clinical Research
Spring Valley, California, 91978, United States
-
Fylde Coast Clinical Research at Layton Medical Centre
Blackpool, Lancashire, FY3 7EN, United Kingdom
-
Hospital San Rafael A Coruna
A Coruña, LA Coruna, 15006, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Hospital Vithas Nisa Sevilla
Castilleja de la Cuesta, Granada, 41950, Spain
-
Juno Research, LLC
Houston, Texas, 77040, United States
-
K2 Medical Research-Winter Garden
Clermont, Florida, 34711, United States
-
Manassas Clinical Research Center
Manassas, Virginia, 20110, United States
-
NexGen Research
Lima, Ohio, 45801, United States
-
Pinnacle Research Group
Anniston, Alabama, 36207, United States
-
Rochester Clinical Research
Rochester, New York, 14609, United States
-
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, 30291, United States
-
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, 78731, United States
-
Universidad de Sevilla - Hospital Universitario Virgen Macarena
Seville, Barcelona, 41009, Spain
-
University Hospitals of Leicester NHS Trust - Leicester General Hospital (LGH)
Leicester, Leicestershire, LE5 4PW, United Kingdom
-
Velocity Clinical Research (Impact Research Institute)
Waco, Texas, 76710, United States
Conditions
Explore the condition pages connected to this study.